nanomedicine-2017-keynote

Page 24

Notes:

Biol Med Case Rep 2017 | Volume 1 Issue 2

allied

academies

November 06-07, 2017 | New Orleans, USA

Nanomedicine & Healthcare

Global Meet on

rug development is a lengthy, complex, and costly process,

entrenched with a high degree of risk and uncertainty that

a drug will succeed to market. A major issue with this process

is associated with the unknown pathophysiology for many

diseases. The brain is enormously complex and that makes

target identification extremely challenging. This is further

complicated by the fact that

In vitro/vivo

models often cannot

simulate the entire disease process. Moreover, other challenges

maybe related to heterogeneity of the patient population and

how those problems might be alleviated with increased clinical

genomic and proteomic data acquisition/mining. These issues

put greater emphasis on human data and how it might lead to

improved target identification and validation. Presently, there

is a lack of validated diagnostic and therapeutic biomarkers

that may objectively detect and measure biological states in

certain stages of the disease process. Recently, precision nano-

theranostics has emerged as an innovative approach to address

these problems. It has been noted in the past as well, that

precision nano-theranostics yields critical molecular imaging

that delivers new target identification and verification and other

important patient data that can aid in the drug development

process. Precision nano-theranostics can offer a powerful

solution to drug discovery, delivery and development by

eliminating the challenges associated with drug development,

allowing for better evaluation of drug activity/efficacy and

toxicity screening, and will benefit the healthcare system by

lowering costs associated with drug development.

Speaker Biography

Dr. Elias Jackson is the Director of Scientific Public Relations for Vyripharm

Biopharmaceuticals, a Biopharmaceutical firm that develops drugs to target cancer,

Neurological disorders and other metabolic diseases. He was previously a professor

and research faculty member at the Cardiovascular Research Center at the Yale

University School of Medicine, and is a graduate of The University of Texas Medical

Branch at Galveston.

Elias Jackson

Vyripharm Biopharmaceuticals, USA

Precision nano-theranostic solutions for drug discovery, development and delivery